Artiva Biotherapeutics (ARTV) Change in Accured Expenses (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Change in Accured Expenses for 4 consecutive years, with -$4.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 329.97% year-over-year to -$4.0 million; the TTM figure through Mar 2026 stood at -$1.1 million (down 173.62% YoY), while the FY2025 annual figure was $2.0 million, up 403.95% from the prior year.
• Change in Accured Expenses slipped to -$4.0 million in Q1 2026 per ARTV's latest filing, from $2.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $3.1 million in Q3 2024 and bottomed at -$4.0 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged -$261363.6 across 4 years, with a median of -$359000.0 in 2023.
• On a YoY basis, Change in Accured Expenses climbed as much as 964.07% in 2024 and fell as far as 793.71% in 2024.
• Artiva Biotherapeutics' Change in Accured Expenses stood at $143000.0 in 2023, then sank by 793.71% to -$992000.0 in 2024, then jumped by 338.41% to $2.4 million in 2025, then plunged by 269.26% to -$4.0 million in 2026.
• Business Quant data shows ARTV's Change in Accured Expenses at -$4.0 million in Q1 2026, $2.4 million in Q4 2025, and $1.1 million in Q3 2025.